Author(s) :

Ellie Yang.

Volume/Issue :

Abstract :

Alzheimer’s Disease (AD) is the most common form of dementia, hallmarked by amyloid-beta (Aβ) plaques, tau tangles, and neuroinflammation. Available therapeutic options have shown only marginal symptomatic relief and have not shown efficacy in halting the progression of the disease, calling for additional therapeutic options. Recently, Curcumin, a bioactive polyphenol extracted from the rhizome of Curcuma longa or turmeric, has gained popularity for its potential neuroprotective activity. However, Curcumin has its own disadvantages, making it important to evaluate synergistic nutraceutical approaches designed to overcome Curcumin’s barriers. Combining Curcumin with other compounds has been shown to compensate for Curcumin’s disadvantages and enhance the efficacy of Curcumin treatment. For example, combining Curcumin with Piperine, Berberine, Resveratrol, and Vitamin D3 has been shown to enhance the bioavailability of Curcumin treatment while helping reduce neuroinflammation, improve memory, or improving the Blood Brain Barrier (BBB). This review explores the combination of Curcumin and several different compounds and found that the Curcumin Piperine combination remains the most promising candidate for clinical standardization due to its direct role in preventing Aβ aggregation. However, current literature is limited by a reliance on in vitro and animal models, alongside inconsistent cognitive outcomes in existing human trials. While these natural synergies still need further research, they represent promising low-toxicity alternatives to traditional pharmaceuticals, but further well-designed, long-term clinical research is essential to establishing them as viable therapeutic options for AD patients.